Abstract:Hana Müllerová, 1 Jeffrey Shi Kai Chan, 2 Heath Heatley, 2 Victoria Carter, 2 John Townend, 2 Derek Skinner, 2 Stefan Franzén, 3 Jonathan Marshall, 4 David Price 2, 5 1 Medical Evidence Strategy, Biopharmaceuticals R&I Medical, AstraZeneca, Cambridge, UK; 2 Observational and Pragmatic Research Institute, Singapore, Singapore; 3 BPM Evidence Statistics, Biopharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden; 4 Global Medical Affairs, Biopharmaceuticals R&I Medical, AstraZeneca, Cambridge, UK; 5 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK Correspondence: David Price, Observational and Pragmatic Research Institute, 22 Sin Ming Lane, &num06 Midview City, Singapore, 573969, Singapore, Tel +65 3105 1489, Email Purpose: Real-life research is needed to evaluate the effectiveness of budesonide/glycopyrrolate/formoterol (BGF) in routine COPD primary care management. We assessed the frequency of medication success among patients with COPD who initiated BGF using real-world data. Patients and Methods: Patients with a recorded diagnostic COPD code who started BGF with ≥ 2 prescriptions within 90-days were identified in the UK Optimum Patient Care Research Database and followed from first prescription until censoring at the end of follow-up (180-days), death, leaving database or end of data at 24/10/2022. The primary outcome was medication success at 90-days post-BGF initiation, defined as no major cardiac or respiratory event (ie no complicated COPD exacerbation, hospitalization for any respiratory event, myocardial infarction, new/hospitalized heart failure, and death) and no incidence of pneumonia. Medication success was also assessed at 180-days post-BGF initiation. Overall real-life medication success was claimed if the lower 95% confidence interval (CI) for the proportion of patients meeting the primary outcome was ≥ 70% (defined a priori). Results: Two hundred eighty-five patients were included. Prior to BGF initiation, these patients often had severe airflow obstruction (mean ppFEV 1 : 54.5%), were highly symptomatic (mMRC ≥ 2: 77.9% (n = 205/263); mean CAT score: 21.7 (SD 7.8)), with evidence of short-acting β 2 -agonist (SABA) over-use (≥ 3 inhalers/year: 62.1%, n=179/285), repeat OCS prescriptions (≥ 2 courses/year: 33.0%, n = 95/285) and multiple primary care consultations (≥ 2 visits/year: 61.1%, n = 174/285). Overall, 39.6% of patients (n = 113/285) switched from previous triple therapies. Real-life medication success was achieved by 96.5% of patients (n = 275/285 [95% CI: 93.6, 98.3]) during 90-days treatment with BGF and by 91.8% (n = 169/184 [95% CI: 86.9, 95.4]) of patients at 180-days. The prescribed daily dose of SABA remained stable over the study period. Conclusion: The majority of patients initiating BGF experienced real-life medication success reflecting the absence of severe cardiopulmonary events. These benefits were apparent after 90-days of treatment and sustained over 180-days. Keywords: death, exacerbation, heart failure, myocardial infarction, pneumonia Worldwide, 10.3% of the population aged 30–79 years are living with chronic obstructive pulmonary disease (COPD), 1,2 ranked as the third leading cause of death globally (responsible for 3.23 million deaths in 2019), and the 7 th leading cause of poor health. 3 In the UK, COPD affects approximately 1.8–2.0% of the population of England and Scotland in 2011, 4 has one of the worst age-standardised years of life lost from COPD in Europe, 5 and has an annual direct healthcare cost estimated to increase to $2.32 billion in England alone by 2030. 4 Patients with COPD are also frequently affected by other comorbidities, particularly cardiovascular disease (CVD) 6 and have a 2–3 fold increased risk of coronary artery disease and other cardiovascular comorbidities. 7–9 The presence of CVD is associated with increased hospitalisation risk, length of hospital stay, and all-cause COPD-related mortality. 6 There is still substantial scope to improve COPD assessment and to optimize treatment to reduce patients' overarching cardiopulmonary risk. 10 COPD is preventable and treatable. 1,3 Triple therapy (ie inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA)) is recommended as an initial treatment option for patients with ≥2 moderate exacerbations (or ≥1 exacerbation leading to hospitalization) with blood eosinophil count (BEC) ≥300 cells/μL, and as follow-up tr -Abstract Truncated-

Budesonide/Glycopyrronium/Formoterol: A Review in COPD

[Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®]

Budesonide/formoterol: a review of its use in asthma

Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease

Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Benefit:Risk Profile of Budesonide in Obstructive Airways Disease

Budesonide/formoterol in the treatment of asthma

Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids

Budesonide + formoterol fumarate dihydrate for the treatment of asthma

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success

TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial

Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial

Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair™ and Trimbow™